Revista
Salud Bosque

ISSN 2248-5759 (impresa) | ISSN 2322-9462 (digital)

REDIB

latindex catálogo 2.0

Artículo de revisión

Historial del artículo:
Recibido: 02 | 10 | 2022
Evaluado: 17 | 11 | 2022
Aprobado: 06 | 12 | 2022
Publicado: 16 | 12 | 2022

Autor de correspondencia:
Kirolos Eskandar
Helwan University – Faculty of Medicine and Surgery
18058@stemegypt.edu.eg

How to cite
Eskandar K. The Medical Aspect of Tobacco Smoke's Adverse Effects on Human Health. Rev. salud. bosque. 2022;12(2):1-14

DOI: https://doi.org/10.18270/rsb.v12i2.2162

The Medical Aspect of Tobacco Smoke's Adverse Effects on Human Health

Kirolos **Eskandar**
Helwan University – Faculty of Medicine and Surgery, Cairo, Egypt

Abstract

According to the Centers for Disease Control and Prevention, there is an annual rate of 7 million deaths because of tobacco use, and this rate is expected to step up to 8 million deaths in 2030 by virtue of smoking-related health complications. Furthermore, it is pathetic to know that almost more than 23% of high school students use tobacco, which if continued at the current rate; about 5.6 million teenagers would be vulnerable to death as mentioned by the World Health Organization. On the other hand, smokers do not only harm themselves but also increase the incidence of pneumonia, asthma, and bronchitis for passive smokers, which by the way contribute to the development of lung cancer and cardiovascular diseases. Moreover, infant death syndrome and slow-growing lung cancer are prevalent in children with continuous exposure to second-hand smoke. These adverse effects emerge from the complex mixture of chemicals present in submicron-sized particles suspended in cigarette smoke like carbon monoxide, benzene, nitrogen oxides, and other gases. Thus, it seems that tobacco smoking has been spreading worldwide as an epidemic with devastating lethal disorders represented in diverse pulmonary, neurological, and cardiovascular-related diseases. Wherefore, this paper discusses the harmful effects of tobacco smoke on human health in accordance with the modern advanced genetic technologies used in exploratory investigations for the relation between smoking and the emergence of human diseases.

Keywords: Cigarette smoke; Cardiovascular diseases; Neurological disorders; Obstructive lung diseases; Asthma; Lung cancer.

Aspectos médicos de los efectos adversos del humo del tabaco y la salud humana

Resumen

Según los Centros para el control y la prevención de enfermedades, la tasa anual de muertes a causa del consumo de tabaco es de 7 millones y se espera que esta tasa aumente a 8 millones en 2030. Además, es lamentable saber que cerca del 23% de los estudiantes de secundaria consumen tabaco y que si esto continúa al ritmo actual, aproximadamente 5.6 millones de adolescentes serían vulnerables a la muerte, según lo menciona la Organización Mundial de la Salud. Los fumadores no solo se causan daño a sí mismos sino que también aumentan la incidencia de neumonía, asma y bronquitis para los fumadores pasivos, y contribuyen al desarrollo de cáncer de pulmón y enfermedades cardiovasculares. Además, el síndrome de muerte infantil y el cáncer de pulmón de crecimiento lento son frecuentes en niños con exposición continua al humo de segunda mano. Estos efectos adversos surgen de la compleja mezcla de sustancias químicas presentes en partículas de tamaño submicrónico suspendidas en el humo del cigarrillo, tales como monóxido de carbono, benceno, óxidos de nitrógeno y otros gases. Así, parece que el tabaquismo se ha ido extendiendo a nivel mundial como una epidemia con devastadores trastornos letales representados en diversas enfermedades pulmonares, neurológicas y cardiovasculares. Por lo tanto, este artículo discute los efectos nocivos del humo del tabaco en la salud humana, de acuerdo con las modernas tecnologías genéticas avanzadas utilizadas en investigaciones exploratorias para la relación entre el tabaquismo y la aparición de enfermedades humanas.

Palabras clave: humo de cigarrillo; enfermedades cardiovasculares; alteraciones neurológicas; enfermedad pulmonar obstructiva crónica; asma; cáncer de pulmón.

Aspetos médicos dos efeitos adversos da fumaça do tabaco e a saúde humana

Resumo

De acordo com os Centros de Controle e Prevenção de Doenças, a taxa anual de mortes por tabagismo é de 7 milhões, e espera-se que essa taxa suba para 8 milhões até 2030. Além disso, é lamentável saber que cerca de 23% dos alunos do ensino médio estudantes usam tabaco e que, se continuar no ritmo atual, aproximadamente 5,6 milhões de adolescentes estariam vulneráveis à morte, segundo a Organização Mundial da Saúde. Os fumantes não apenas prejudicam a si mesmos, mas também aumentam a incidência de pneumonia, asma e bronquite para fumantes passivos e contribuem para o desenvolvimento de câncer de pulmão e doenças cardiovasculares. Além disso, a síndrome da morte infantil e o câncer de pulmão de crescimento lento são comuns em crianças com exposição contínua ao fumo passivo. Esses efeitos adversos surgem da complexa mistura de produtos químicos presentes em partículas submicrométricas suspensas na fumaça do cigarro, como monóxido de carbono, benzeno, óxidos de nitrogênio e outros gases. Assim, parece que o tabagismo vem se espalhando mundialmente como uma epidemia com desordens letais devastadoras representadas em várias doenças pulmonares, neurológicas e cardiovasculares. Portanto, este artigo discute os efeitos nocivos da fumaça do tabaco na saúde humana, de acordo com as modernas tecnologias genéticas avançadas utilizadas em pesquisas exploratórias para a relação entre o tabagismo e a ocorrência de doenças humanas.

Palavras-chave: fumaça de cigarro; doenças cardiovasculares; problemas neurológicos; doença pulmonar obstrutiva crônica; asma; cancer de pulmão.

Introduction

As per statistical findings gathered from different countries, the number of smokers globally is thought to be over 1.1 billion; 200 million are women while the rest are men. In addition, it is gauged that men outnumber women by a ratio of 2:1 in wealthy countries whereas 7:1 in underdeveloped ones [1]. Although the number of smokers in the U.S. declined relatively since 1967, cigarette manufacturing is still at a consistent rate to fulfill the burgeoning export needs brought on by the rising tobacco consumption in the rest of the globe, particularly in far eastern Asia [1, 2]. There is enough evidence to show that cigarette smoke is an extremely complex combination of around 4790 distinct components, and about 100 of them are recognized as mutagens and carcinogens. In addition to the inclusion of gases, this combination also comprises around 10 different-sized particles per milliliter of mainstream (MS) smoke, alongside hydrogen cyanide (HCN), which has a deleterious impact on the respiratory tract and causes nerve damage in cigarette smokers with ophthalmic neuropathy [3]. Additionally, smoke's oxidation-reduction state is central as oxidants affect how cholesterol-filled plaques in the coronary arteries can mature. Since they are thought to be responsible for addiction, smoking behavior, and quitting, tobacco alkaloids have received more attention due to their pharmacological action, which has been a subject of extensive research for several years [4]. It is also observable that rather than being caused by the impacts of a single component of smoke, the health effects of this lethal combination are more likely to be caused by the cumulative impact of these chemicals through a number of synchronized processes. According to laboratory studies in Europe, MS and side-stream (SS) cigarette smoke include both long- and short-lived radicals that are linked to a number of smoking-related diseases [5, 6].

Other studies in 2005 have shown that smoking has contributed to 12.5 million deaths in the U.S. since 1965, costing the country over $167.8 billion annually. Unfortunately, It is anticipated that in the next 20 to 30 years, tobacco-related illnesses will become a global epidemic in a number of nations based on consumption and disease prevalence patterns [7]. Likewise, tobacco-related mortality is expected to almost triple globally in the next 15 to 20 years, where almost every day, 2730 individuals in the U.S. die from cardiovascular-related disorders, which have intensified fourfold because of smoking, equating to one death every 31 seconds [8]. In developed nations, smoking is already the leading cause of adult mortality, and that tobacco usage is anticipated to surpass all other causes of death during the next several decades. Unluckily, the worst is yet to come for most nations, according to predictions, since there will be around 10 million tobacco-related fatalities annually by the time today's youthful smokers reach middle or old age [9]. Contrary to popular belief, nonsmokers live longer and die of cancer at a slower rate than smokers. So that, the paper spots the light on the lethal effects that could emerge from both SS and MS smoke.

Pulmonary Diseases

The etiology of numerous forms of lung illnesses has been related to smoking, however, nonsmokers exposed to ambient tobacco smoke experience fluctuations in lung functions. Where passive smoking is substantially related to nocturnal chest tightness and dyspnea, breathing difficulty after exertion, and enhanced bronchial reactivity, as indicated by epidemiological research done in Europe involving 7861 teenagers [10, 11]. Furthermore, the abnormalities in the pulmonary structures and functions which are subsidized by cigarette smoke, define chronic obstructive pulmonary disease (COPD) by meddling with the capacity of airway epithelial cells to promote healing processes. Recent studies have shown that acrolein and acetaldehyde, two volatile constituents present in cigarette smoke extract (CSE), are capable of preventing human airway epi-

thelial cells from chemotactic movements, multiplication, and abridgment in 3-D collagen gels that portray the remodeling of the extracellular matrix [12]. On the contrary, although they showed no action towards multiplication and abridgment, the non-volatile constituents hindered chemotactic movements. These two findings imply that tobacco use might be one of the factors that promote architectural alterations in the airways aligned in COPD [13]. The two forms of COPD, emphysema, and bronchitis, are considered the most significant reasons for illness and death, especially in the U.S, where there are 2.4 and 13.2 million adults affected with emphysema and bronchitis respectively, as indicated by the latest estimates. In fact, there are multiple causes aside from cigarette smoking like infectious and allergic disorders, genetic backgrounds, and pollution for the emergence of COPD. By now, it is justified why smokers have greater rates of COPD-related deaths [14, 15].

Also, among the drawbacks of smoking, is that it reduces the lungs' surfactant, which functions mainly to increase the alveolar surface area. In addition to the abnormal extension of alveoli, prolonged cigarette smoke is found to cause rats' hypertrophic type 2 cells [16]. Conversely, other researchers have found that the proportion of phospholipids in the lung's airway, is mostly the same in non-smokers and smokers. Briefly, these conflicts indicate that as a consequence of smoke's dissimilar composition, cigarette smoke has complicated impacts on cells that produce surfactant and surfactant concentration. So that, the paper spots the light on the lethal effects that could emerge from both SS and MS smoke [17]. In 2003, a group of biochemistry researchers in the U.S performed research trials on guinea pigs once exposed to whether passive or direct cigarette smoke. They found out that there is extensive damage in the pigs' lungs mediated by free radicals and the anesthetization of Beta-Adreno-receptors in alveolar type-2 cells. Considering that surfactant production is intervened via the catecholamine present on particular Beta-Adreno-receptors in the lungs, that is why there is a considerable decrease in surfactant emanation once upon smoke exposure [18, 19]. Another recent study on the same kind of pigs has shown that there is a considerable upsurge in the amount of phospholipid-binding protein (PLBP) in the alveolar type-2 cells after they are subjected to cigarette smoke, while it is yet unclear exactly how smoking brings about this alteration [20].

Asthma

There is a strong consensus that cigarette smoke has negative impacts on asthma, where its risk is exaggerated in the case of children who get exposed to SS smoke or what is known as environmental tobacco smoke (ETS), particularly through parental smoking. Furthermore, patients with asthma and other chronic diseases are prone to deteriorated lung functions, more oppressive symptoms, and thus an impoverished quality of life in case of their exposure to ETS smoke [21]. Recently, it has been shown that active smoking is not considered to be a substantial risk factor for asthma, but it is linked to worsened results in terms of lung function disturbances and asthma-related fatality. Therefore, taking into account the current understanding, it appears to be critical to advise asthma sufferers not to smoke [22]. A Swedish study was undertaken to determine if children in a metropolitan population who get exposed to ETS are affected with asthma and other lower airway irritants (LAWI) when becoming adults? Unfortunately, the answer to this question was "YES", they have found that adults who were exposed to ETS when they were children, increased the incidence of asthma among them even those who had never smoked a cigarette [23, 24]. Also, after ETS was discovered to be a significant LAWI, it has been noted that those children are more prone to start smoking at an older age. Studies have demonstrated that spouses who are married to non-smokers, excrete 3 times less urinary cotinine than the amount of those parents who are married to smokers.

Accordingly, skin test hyper-reactivity to asthmatics and aeroallergens, is more common in children whose parents are smokers, in addition to lung function impairment in those children as well [25].

Although there is a proven correlation between smoking and COPD emergence, there is a debate regarding how exposure to ETS may exacerbate it. Despite the presence of ciliated pseudostratified columnar epithelium lining the respiratory tract and acting as a pillar to prevent contaminants from diffusing into the lungs, allergens whether mite or occupational ones, can induce airway hyper-reactivity which is made worse by cigarette smoke and other prevalent air pollutants [26]. Besides, a direct relationship between smoking and β-2-adrenergic receptor gene polymorphism in the presence of asthma has been proven. Also, it is noteworthy that a population-based study done in Germany discovered that cigarette smoke causes higher respiratory issues in women than in men.

Cardiovascular Diseases

Numerous cardiovascular illnesses, including myocardial infarction, coronary heart disease, type 2 diabetes mellitus, hypertension, poor cardiopulmonary function, and reduced exercise tolerance have been linked to smoking [27]. Free radicals inhaled with smoking and the elevated amounts of reactive oxygen derivatives produced in smokers' lungs by phagocytes are likely to reach the circulation, alter the blood's antioxidant enzyme activities, and ultimately lead to cardiovascular issues. Smoking's effects on the activity of antioxidant enzymes are debatable, though [28]. According to studies, smoking reduces the antioxidant activity in smokers' serum and causes an increase in hemoglobin and ceruloplasmin levels but has little to no influence on the antioxidant enzyme activities in smokers' blood [29, 30]. Additionally, it was discovered that smokers' alveolar macrophages contain higher levels of iron and ferritin. It is possible that changes in iron metabolism brought on by smoking will increase the amount of iron that is available for oxidative reactions and reduce the serum antioxidant activity of smokers [31]. In experiments on animals using the guinea pig as a model, both direct and passive smoking caused an increase in the activity of superoxide dismutase, a decrease in the activities of glutathione peroxidase and NADPH-producing enzymes, and no change in the activity of catalase in erythrocytes [32]. Smoking has been demonstrated to lower men's serum bilirubin concentrations in an epidemiological study conducted in Belgium. Poorer levels of bilirubin in smokers may be related to lower antioxidant activity because endogenous blood bilirubin is known to have antioxidant activity [33]. Environmental-tobacco-smoking is a significant contributor to the development of cardiovascular illnesses. Children exposed to passive smoking have harm to their endothelial blood vessel cells as early as their first month of birth, and these flaws can be seen in the first ten years of life. ETS increases the thickness of the vessel wall over a period of more than ten years, which alters the intima/media ratio [34]. Furthermore, smoking has been linked to serious negative effects on cardiac function and exercise tolerance, especially in children.

Atherosclerosis –the accumulation of fats and cholesterol on arterial walls- is one of the leading factors for the continuous increase in mortality rate as a reason for cardiovascular disorders. Where the process of atherosclerotic plaque formation known as atherogenesis, is the primary causative agent of CAD [35]. Furthermore, it is worth mentioning that cigarette smoke helps to build and promote atherogenesis both individually and in concert with other adverse outcomes including hyperlipidemia and hypertension. Several studies have demonstrated that the likelihood of developing Coronary artery disease rises with daily cigarette use, lifetime smoking years, and age of starting tobacco smoking, demonstrating a direct relation between smoking dose and deterioration of human health [36, 37]. The processes through which smoking affects the

onset and advancement of atherosclerosis are not fully adequately documented, but newfangled research indicates that smoking has a negative impact on the activities of smooth muscle cells and endothelial cells, in addition to the disruption of thrombotic processes caused by tobacco smoke [38]. Three separate investigations conducted on 3 different continents using contemporary ultrasonography technology have shown that both SS and MS smoke causes a notable handicapped endothelium-dependent vasoregulation and by the way, may affect nitric oxide (NO) synthase on endothelial cells negatively [38, 39]. On the other hand, those who were second-hand smokers and avoided smoke-contaminated surroundings, have demonstrated that endothelial function has been recovered to some extent.

Recent findings have approved that genetic mutations in the endothelium nitric oxide-synthase gene were found to be related to smokers' increased risk of developing coronary artery disease. Also, researchers contend that tobacco smoke intertwines with the metabolism of C6H14N4O2 and NO, thus reducing NO synthesis [40]. Moreover, it has been observed that tobacco smoke exposure stimulates leukocytes and endothelium attachment, in addition, it upregulates the production of adhesion molecules and endothelial cells. Meanwhile, the activation of a particular adhesion molecule is decided in vivo, and it is unclear how these different events are related to one another [41]. Likewise, it is well understood that cigarette smoke exposure causes the body to experience more production of free radicals through a number of processes, including the reduction of plasma antioxidants like α-tocopherol. In addition, the significance of oxidative stress in enhancing leukocyte-endothelial interactions that increase before the onset of arteriosclerosis in smokers has been investigated in at least three research projects [42]. On the contrary, it is been approved that smokers who consume large amounts of antioxidants have less of their monocytes' ability to adhere to endothelial cell walls.

Other trials have been performed by collecting serum samples from adolescent smokers after and before every oral dose of C6H14N4O2 and Vit. C, where these samples were examined for their ability to enhance human monocyte's adhesion to human umbilical vein endothelial cells' monolayers [43]. It was demonstrated that whereas oral C6H14N4O2 reduced this leukocyte adhesion, Vit. C supplements had no such effect, which means that, at least in the beginning, Nitric Oxide' levels might have a role in the interactions between leukocytes and endothelial cells brought on by tobacco smoke [44]. Moreover, it is found that second-hand smokers have larger volumes of 8-OHdG and F2-isoPs which are oxidized DNA and arachidonic acid products respectively. Other findings revealed that there is a large number of auto-antibodies against oxidized LDL, which is a key risk factor for the development of atherosclerosis, in tobacco smokers [45]. However, these LDL autoantibodies are discovered to be reduced significantly once adding C29H50O2 -a lipid-soluble antioxidant- to one's diet. Additionally, it was shown that consuming a combination of antioxidants increased smokers' LDL's resistance to oxidative reconfiguration and decreased the serum concentration of 8-OHdG in second-hand smokers [46]. As a result, this research work has discovered novel, more precise indicators of oxidative stress which could be employed as biological diagnostics of oxidant damage and exploited to design nutritional and pharmaceutical therapies against the illness' onset. There have been very few investigations on the cardiovascular consequences of cigarette smoke in experimental mice models; yet, these studies in animals are required to define the part played by various pathways in increasing atherosclerotic disease and to design effective therapies [47, 48].

Neurological Disorders

As part of the 1996 Finnish Health Care Survey, 5994 non-institutionalized Finns between the ages of 15 and 75 were chosen at random and interviewed. This study looked into the relationships between major depressive episodes and drinking alcohol and smoking cigarettes [49]. According to the poll, drinking too much alcohol and smoking cigarettes are significant risk factors for depressive episodes. Smoking had a higher negative effect on this population. An outpatient psychiatric center's retrospective examination of 934 individuals reveals a high correlation between smoking and mental health issues. Smoking was finally acknowledged as a risk factor for ischemic stroke at the end of the 1980s [50]. More recently, the effects of smoking on Parkinson's disease and Alzheimer's disease have been investigated. Numerous epidemiological studies have discovered a very strong link between smoking and these two neurogenerative diseases. The risk of Parkinson's disease and Alzheimer's disease has typically been about twice as high in nonsmokers as it is in smokers [51]. This has been interpreted as indicating that smoking has an ill-defined, biological effect that protects the brain from the onset of Parkinson's disease and Alzheimer's disease. Numerous epidemiological studies have shown how smoking has a protective impact against Parkinson's disease, however, there have been inconsistent findings regarding how smoking affects Alzheimer's disease. Cohort and case-control studies yield contradictory findings about the direction of the link between smoking and Alzheimer's disease [52]. This disparity may be partially explained by survival bias and other case-control study methodological issues.

Lung Cancer

Structured and non-structural defensive mechanisms are present in healthy lungs to thwart the effects of potentially harmful chemicals in the inhaled air. The structural defenses can be changed by illness or dietary deficiencies, which can also start a vicious cycle that leads to first lung damage [53]. For instance, it has been demonstrated that singlet molecular oxygen is produced in biological systems in response to environmental damage and is capable of harming proteins, lipids, and DNA. Superoxide dismutase, glutathione peroxidase, glutathione-S-transferase, and reduced glutathione are components of the non-structural or biochemical defense system that shield the lung against reactive metabolites and harmful oxygen species produced by the pulmonary metabolism of foreign substances [54, 55]. Smoke activates these metabolic defenses and is thought to have a role in lung cancer. Meanwhile, it has been demonstrated that vitamin A intake is negatively correlated with lung cancer rates. Additionally, studies have already confirmed that vitamin A guards against lung malignancies linked to tobacco use.

By the end of the 20th century, tobacco-related lung cancer—once thought to be a rare disease in the 19th—had become the most aggressive and deadly cause of cancer mortality [56]. Because the majority of tobacco-related disease is characterized by long-term cumulative harm or change, the disease consequence of smoking affects the elderly disproportionately. Cigarette smoking is the most potent risk factor for lung cancer in women, according to a Polish study. Small cell carcinoma and squamous cell carcinoma showed the largest effects of this component [57]. Additionally, it has been shown that exposure to passive smoking while still a child and before the age of 18 dramatically raised the risk of developing squamous cell carcinoma, small cell carcinoma, and cancers of all cell types. Adenocarcinoma also showed a comparable effect [58, 59]. According to a New South Wales epidemiological study, nonsmokers exposed to ETS had a higher risk of developing lung cancer. The increased risk of lung cancer linked to ETS has been confirmed by numerous other investigations.

Additionally, tobacco smoke is a known human carcinogen that contains more than 50 different carcinogens, with polycyclic aromatic hydrocarbons (PAHs) and tobacco-specific nitrosamines ranking among the most dangerous of them (TSNs) [60]. Tar and nicotine concentrations in cigarettes have declined during the past 40 years, along with the concentration of PAHs; nevertheless, TSN concentrations have gone up. The quantity of cigarettes smoked each day, the kind of cigarette, smoking topography, carcinogen metabolism, and DNA repair are some of the elements that affect the biologically effective dose of carcinogens [61]. Numerous studies have demonstrated a link between tobacco smoke exposure, the development of carcinogen-DNA adducts, tumor-specific mutations, and the chance of developing cancer.

Environmental Tobacco Smoke

Although it is commonly understood that tobacco smoke has direct devastating consequences on human health, composed of multiple carcinogens and that it is proven to be one of the main causative agents for lung cancer and COPD, however, these repercussions are accepted for active smokers but not for those who get exposed to ETS unintentionally [62]. In the last five years, data have been gathered about the causative agents for pulmonary disorders, and for non-smokers, it is found that ETS is the principal contributor to toxins exposure through breathing. In spite of the current several prohibitions and the sporadic reporting on its effects on non-smokers, tobacco smoking is still prevalent in public places [63]. Nowadays, ETS is considered a serious risk for the emergence of cardiovascular and pulmonary disorders in passive smokers, after it was given slight alertness until 1990. Furthermore, in comparison to non-smoking parents, lung malfunction, longer bedtime, and more hospitalization are ubiquitous among children of smoking parents because of their repetitive exposure to ETS [63, 64]. Those who are aged between 16 and 66, are also thought to develop atherosclerosis as indicated by extensive research estimating the quantitative risk of developing atherosclerosis in 11,000 adults by assessing the intimal-medial cross-sectional area of the carotid artery. Where the results of this study were an increase of 51%, 21%, and 26% for ongoing, passive, and former smokers respectively over non-smokers in the emergence of atherosclerosis once exposed to any type of tobacco smoke [64].

As per a retrospective analysis of 19 epidemiological studies, there is an elevated ratio of coronary artery disease' risk factors for those who are in continuous exposure to ETS, where risks are more serious with women [65]. Additionally, researchers discovered a substantial dose-response correlation between passive smokers' risk of developing coronary artery disease and the intensity of smoke exposure. Despite the ongoing controversy regarding ETS exposure and tobacco smoke-related malignancies, there is a compelling case for starting experimental investigations to support human data and uncover pathophysiology [65]. Accordingly, more countries are putting more restrictions that limit active smoking within popular areas aiming to decrease environmental tobacco smoke and thus the related pathological disorders in second-hand smokers.

Concluding Remarks for Tobacco Smoking Future Research

The Comprehensive epidemiological investigations supplemented with precise molecular genotyping of distinct populations are expected to yield the greatest benefits. Where this kind of study help reassess the pervasiveness of tobacco smoking and pinpoint the precise nature of tobacco-related disorders' recurrence, the involvement of contributing variables like nutritional status, exposure to other narcotics, and the genetic make-up of population subgroups vulnerable to substantial risk. Moreover, to inspect smokers and nonsmokers for a range of health issues, several molecular and biochemical diagnostics will need to be used. Analyzing the findings from these surveys, will assist clarify corre-

lations between various epidemiological metrics and help discover the key interacting variables for diverse health concerns. Therefore, to carry out these integrated human investigations in fields and laboratories, it would seem necessary to put together teams of interdisciplinary researchers, specialists, and scholars. On the other hand, it is difficult to carry out such prosecutions due to the constraints of resources and conflicting demands for research funding, as such research work and investigations would require generous funding, investment of time, and resources in order to procure valuable records and data. Thus, the other best course of action for smoking and health programmes is probably experimental investigations with animal models utilizing inhalation exposure to entire smoke rather than particular smoke components.

The population-based epidemiological studies discussed in the present review have uncovered a number of genes that seem to have a distinctive role in a variety of tobacco-related disorders, including malignancies in particular. Where it has been challenging to precisely determine the role of several putative genes in tobacco tumorigenesis as it has been complicated to manage all the varied parameters in human studies. It is preferable to exploit the presence of variegation of transgenic experimental animals as an initiative and use them to perform tentative trials targeting tobacco smoke-related health disorders and thus the ascertained data to be used in finding out the relation of distinct genes in the pathophysiology of these disorders, explicate the process through which these diseases develop and discover different agents with pharmacological preventative potential. Focusing on investigations of the in vivo consequences of inhaled entire cigarette smoke in experimental animals with known unique genetic makeup might help future research in the domain of tobacco use and health. In addition, the knowledge gleaned from human molecular epidemiology research would need to be carefully taken into account when choosing the genetic make-up. As previously mentioned, a number of genes have a significant impact on the emergence of disorders linked to smoking. In this perspective, there are currently a large number of relevant recombinant and knock-out animals that may be utilized to analyze tobacco-related disorders.

Declarations

Not applicable

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable

Acknowledgements

Not applicable

References

1. Kirby JB. The influence of parental separation on smoking initiation in adolescents. J Health Soc Behav. 2002;43(1):56–71.

   https://doi.org/10.2307/3090245

2. Trends in cigarette smoking among high school students – United States, 1991–1999. MMWR Morb Mortal Wkly Rep 49: 755–758, 2000.

3. John U, Hanke M: Tobacco smoking attributable mortality in Germany. Gesundheitsaesen. 2001Jun;63(6):363–369. German.

https://doi.org/10.1055/s-2001-15684

4. Criado-Alvarez JJ, Morant Ginestar C, de Lucas Veguillas A. Mortality attributable to tobacco consumption in the years 1987 and 1997 in Castilla la Mancha, Spain. Rev Esp Salud Publica 2002;76:27–36.

http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1135-57272002000100004&lng=es.

5. Lam TH, Jiang CQ, Ho SY, Zhang WS, Liu WW, He JM: Smoking and mortality in 81,344 drivers in Guangzhou, China. Occup Environ Med. 2002;59:135–138.

https://doi.org/10.1136/oem.59.2.135

6. Marable S, Crim C, Dennis GC, Epps RP, Freeman H, Mills S, Coolchan ET, Robinson L, Robinson R, Cole L, Payne PH: Tobacco control: Consensus report of the National Medical Association. J Natl Med Assoc. 2002;94: 78–87.

7. Turner J, Page-Shafer K, Chin DP, Osmond D, Mossar M, Markstein L, Huitsing J, Barnes S, Clemente V, Chesney M: Pulmonary Complications of HIV Iinfection Study Group: Adverse impact of cigarette smoking on dimensions of health-related quality of life in persons with HIV infection. AIDS Patient Care STDS. 2001;15:615–624.

https://doi.org/

8. Vogt MT, Hanscom B, Lauerman WC, Kang JD: Influence of smoking on the health status of spinal patients: The National Spine Network database. Spine 27: 313–319, 2002.

https://doi.org/10.1089/108729101753354617

9. Berard RM, Lockhart IA, Boermeester F, Tredoux C: Cigarette smoking in an adolescent psychiatric population. S Afr Med J 2002;92: 58–61.

10. Platts-Mills TAE, De Weck AL. House dust mites: A world wide problem. J Allergy Clin Immunol. 1989;83:416–427.

11. Auerbach O, Hammond EL, Garfinker L, Benante C: Relation of smoking and age to emphysema. Whole-lung section study. N Eng J Med. 1972;286:853-857.

https://doi.org/10.1056/NEJM197204202861601

12. Mukherjee S, Das SK: Effects of cigarette smoke exposure on the binding capacity of β-adrenergic receptors in guinea pig alveolar type II cells. FASEB J 1992;6:259.

13. Laniado-Laborín R. Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. Int J Environ Res Public Health. 2009 Jan;6(1):209-24.

https://doi.org/10.3390/ijerph6010209. Epub 2009 Jan 9. PMID: 19440278; PMCID: PMC2672326.

14. Haagsman HP, Van Golde LM. Lung surfactant and pulmonary toxicology. Lung 1985;163:275-303.

https://doi.org/ 10.1007/BF00180279

15. Mancini NM, Bene MC, Gerard H, Chabot F, Faure G, Polu JM, Lesur O. Early effects of short-time cigarette smoking on the human lung: A study of bronchoalveolar lavage fluids. Lung 1993;171: 277-291.

https://doi.org/ 10.1186/1617-9625-2-1-3

16. Le Mesurier SM, Stewart BW, Lykke AW. Injury to type-2 pneumocytes in rats exposed to cigarette smoke. Environ Res. 1981;24: 207-217.

https://doi.org/10.1016/0013-9351(81)90146-8.

17. Zetterberg G, Curstedt T, Eklund A. A possible alteration of surfactant in broncho-alveolar lavage fluid from healthy smokers compared to non-smokers and patients with sarcoidosis. Sarcoidosis 1995;12:46-50.

18. Subramaniam S, Bummer P, Gairola CG. Biochemical and biophysical characterization of pulmonary surfactant in rats exposed chronically to cigarette smoke. Fundam Appl Toxicol 1995;27:63-69.

https://doi.org/ 10.1165/ajrcmb.25.6.4458

19. Wang H, Liu X, Umino T, Skold CM, Zhu Y, Kohyama T, Spurzem JR, Romberger DJ, Rennard SI. Cigarette smoke inhibits human bronchial epithelial cell repair processes. Am J Respir Cell Mol Biol 2001;25: 772-779.

https://doi.org/10.1165/ajrcmb.25.6.4458

20. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction. Am Rev Respir Dis. 1983;128:833-838.

https://doi.org/10.1164/arrd.1983.128.5.833.

21. Ulrik CS, Lange P. Cigarette smoking and asthma. Monaldi Arch Chest Dis. 2001;56:349-353.

22. Mukherjee S, Woods L, Weston Z, Williams AB, Das SK: The effect of mainstream and sidestream cigarette smoke exposure on oxygen defense mechanisms of guinea pig erythrocytes. J Biochem Toxicology.1993;8:119-125.

https://doi.org/ 10.1002/jbt.2570080303.

23. Louie D. The effects of cigarette smoking on cardiopulmonary function and exercise tolerance in teenagers. Can Respir J 2001;8: 289–291.

https://doi.org/ 10.1155/2001/701384.

24. Gladston M, Feldman JG, Levytska V, Magnusson B. Antioxidant activity of serum ceruloplasmin and transferring available iron-binding capacity in smokers and non-smokers. Am Rev Respir Dis. 1987;135:783– 787, 1987.

https://doi.org/10.1164/arrd.1987.135.4.783.

25. Strain JJ, Carville DGM, Barker ME, Thompson KA, Welch RW, Young P, Rice DA. Smoking and blood antioxidant enzyme activities. Biochem Soc Trans. 1989;17:497–498.

https://doi.org/10.1002/jbt.2570080303

26. McGowan SE, Henley SA. Iron and ferritin contents and distribution in human alveolar macrophages. J Lab Clin Med 1988;111: 611–617.

https://doi.org/10.2147/COPD.S138457.

27. Criqui MH, Cowan LD, Tyroler HA, Bangdiwala S, Heiss G, Wallace RB, Cohn R. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality: results from the Lipid Research Clinics Follow-up Study. American Journal of Epidemiology. 1987;126(4):629–37.

https://doi.org/10.1093/oxfordjournals.aje.a114702.

28. Dagenais GR, Robitaille NM, Lupien PJ, Christen A, Gingras S, Moorjani S, Meyer F, Rochon J. First coronary heart disease event rates in relation to major risk factors: Quebec Cardiovascular Study. Can J Cardiol. 1990;6(7):274–80.

29. Haustein KO. Health consequences of passive smoking. Z Arztl Fortbild Qualitatssich 2001;95:377–386, 2001.

30. Eliasson M, Lundblad D, Hagg E. Cardiovascular risk factors in young snuff-users and cigarette smokers. J Intern Med. 1991;230(1):17–22.

https://doi.org/10.1111/j.1365-2796.1991.tb00401.x.

31. Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation 2005;112(4):489–97.

https://doi.org/10.1161/CIRCULATIONAHA.104.521708

32. Iribarren C, Tekawa IS, Sidney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med. 1999;340(23):1773–80.

https://doi.org/10.1056/NEJM199906103402301

33. Joseph AM, Fu SS. Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovascular Dis. 2003;45(6):429–41.

https://doi.org/10.1053/pcad.2003.YPCAD14.

34. Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens Suppl. 1990;8(Suppl 5):S3–S8.

https://doi.org/

35. Koenig W, Sund M, Fröhlich M, Fischer H-G, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 Jan 19;99(2):237-42.

https://doi.org/ 10.1161/01.cir.99.2.237.

36. Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol. 1993 Nov 15;22(6):1697-702.

https://doi.org/10.1016/0735-1097(93)90598-u.

37. Kiyohara Y, Ueda K, Fujishima M. Smoking and cardiovascular disease in the general population in Japan. J Hypertens Suppl. 1990;8(Suppl 5):S9–S15.

38. Kannel WB, McGee DL, Castelli WP. Latest perspectives on cigarette smoking and cardiovascular disease: the Framingham Study. J Cardiac Rehab. 1984;4(7):267.

39. Kugiyama K, Yasue H, Ohgushi M, Motoyama T, Kawano H, Inobe Y, Hirashima O, Sugiyama S. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. J Am Coll Cardiol. 1996;28(5):1161–7.

https://doi.org/ 10.1016/S0735-1097(96)00325-7.

40. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. Progress Cardiovasc Dis. 2003;46(1):31–8.

https://doi.org/10.1016/S0033-0620(03)00078-1

41. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298(10):1180–8.

https://doi.org/10.1001/jama.298.10.1180.

42. Lightwood J. Economics of smoking and cardiovascular disease. Progress Cardiovasc Dis. 2003;46(1):39–78.

https://doi.org/10.1016/S0033-0620(03)00077-X

43. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96(1):168–73.

https://doi.org/10.1046/j.1365-2141.1997.8532481.x.

44. Lu JT, Creager MA. The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med. 2004;5(4):189–93.

45. Mahmarian JJ, Moyé LA, Nasser GA, Nagueh SF, Bloom MF, Benowitz NL, Verani MS, Byrd WG, Pratt CM. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol. 1997;30(1):125-130.

46. Metz L, Waters DD. Implications of cigarette smoking for the management of patients with acute coronary syndromes. Prog Cardiovasc Dis. 2003 Jul-Aug;46(1):1-9.

https://doi.org/10.1016/s0033-0620(03)00075-6.

47. Meyers DG, Neuberger JS, He J. Cardiovascular effects of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol. 2009 Sep 29;54(14):1249-55.

https://doi.org/10.1016/j.jacc.2009.07.022. Erratum in: J Am Coll Cardiol. 2009 Nov 10;54(20):1902.

48. Neunteufl T, Heher S, Kostner K, Mitulovic G, Lehr S, Khoschsorur G, Schmid RW, Maurer G, Stefenelli T. Contribution of nicotine to acute endothelial dysfunction in long-term smokers. J Am Coll Cardiol. 2002 Jan 16;39(2):251-6.

https://doi.org/10.1016/s0735-1097(01)01732-6.A.

49. Aromaa, & S. Koskinen (Eds.), (1996). Health and functional capacity in Finland. Baseline results of the Health 2000 Health Examination Survey. Helsinki: National Public Health Institute, Department of Health and Functional Capacity.

50. G SB, Choi S, Krishnan J, K R. Cigarette smoke and related risk factors in neurological disorders: An update. Biomed Pharmacother. 2017 Jan;85:79-86

https://doi.org/10.1016/j.biopha.2016.11.118.

51. Platts-Mills TAE, De Weck AL. House dust mites: A world wide problem. J Allergy Clin Immunol 1989;83:416–427.

https://doi.org/10.1016/0091-6749(89)90128-0.

52. Fratiglioni L, Wang HX: Smoking and Parkinson's and Alzheimer's disease: Review of the epidemiological studies. Behav Brain Res 2000;113:117–120.

https://doi.org/ 10.1016/s0166-4328(00)00206-0

53. Almeida OP, Hulse GK, Lawrence D, Flickler L: Smoking as a risk factor for Alzheimer's disease: Contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002;9: 15–28.

https://doi.org/10.1046/j.1360-0443.2002.00016.x.

54. Charpin D, Kleisbauer JP, Lanteaume A, Razzouk H, Vervloet D, Toumi M, Faraj F, Charpin J: Asthma and allergy to house-dust mites in populations living in high altitude. Chest 1988;93:758–761.

https://doi.org/10.1378/chest.93.4.758.

55. Andrae SO, Axelson O, Bjorksten B, Fredriksson M, Kjellman NIM: Symptoms of bronchial hyperreactivity and asthma in relation to environmental factors. Arch Dis Child 1988;63: 473–478.

https://doi.org/10.1136/adc.63.5.473.

56. Tager IB. Passive smoking-bronchial responsiveness and atopy. Am Rev Respir Dis 1988;138:507–579.

https://doi.org/ 10.1164/ajrccm/138.3.507.

57. Garcia-Closas M, Kelsey KT, Wiencke JK, Xu X, Wain JC, Christiani DC. A case control study of cytochrome P450 1A1, glutathione S transferase M1, cigarette smoking and lung cancer susceptibility. Cancer Causes Control 1997;8:544-53.

https://doi.org/ 10.1023/a:1018481910663.

58. Vineis P, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase metabolic polymorphism and low level environmental exposure to carcinogens. Nature. 1994;369:154-6.

https://doi.org/10.1038/369154a0.

59. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-25.

60. Rebbeck T. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-43.

61. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen DK, Vainio H. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis 1994;15:813-5.

https://doi.org/ 10.1093/carcin/15.5.813.

62. Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J Natl Canc Inst. 1995;87:902-7.

https://doi.org/10.1093/jnci/87.12.902.

63. Glantz S, Parmley WW. Passive smoking and heart disease: Mechanisms and risk. JAMA. 1995;273:1047–53.

64. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1–1438.

65. Howard G, Wagenknecht LE, Diez-Roux A, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA. 1998;279:119–24.

https://doi.org/10.1001/jama.279.2.119.

66. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N Engl J Med. 1999;340:920–6.

https://doi.org/10.1056/NEJM199903253401204.